GlassScriptPhysician profile
Michael A Parker
NPI 1457848913
$68,934.77
in general payments reported to CMS, 2019-2025
23 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $15K · 2023: $8,015 · 2024: $7,569 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Honoraria: $9,625 · Food and Beverage: $3,058 · Travel and Lodging: $1,809 · Consulting Fee: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,941.25 |
| Honoraria | $9,625.00 |
| Food and Beverage | $3,058.45 |
| Travel and Lodging | $1,808.83 |
| Consulting Fee | $670.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $40,010.61 | 2021-2025 | |
| Axsome Therapeutics, INC. | $11,611.24 | 2025 | Symbravo |
| Allergan, INC. | $6,178.38 | 2021-2022 | |
| Pfizer INC. | $4,700.57 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $4,402.19 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $868.75 | 2022 | |
| Amgen INC. | $347.67 | 2021-2023 | Aimovig |
| Lilly USA, LLC | $232.01 | 2021-2024 | Emgality, Reyvow |
| Biogen, INC. | $132.24 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $62.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $55.54 | 2021-2025 | Ajovy |
| Genentech USA, INC. | $53.39 | 2021-2023 | Ocrevus |
| Otsuka America Pharmaceutical, INC. | $51.81 | 2025 | Rexulti |
| Lundbeck LLC | $35.03 | 2022 | |
| Amneal Pharmaceuticals LLC | $32.99 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $29.77 | 2021 | |
| Endo Pharmaceuticals INC. | $23.19 | 2022 | |
| Genentech, INC. | $22.68 | 2024 | Ocrevus |
| Csl Behring | $21.44 | 2021 | |
| Sk Life Science, INC. | $17.16 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.39 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $15.40 | 2023 | Dysport |
| Merz Pharmaceuticals, LLC | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.